Skip to content
Sanatan Upmanyu

Hi, I’m Sanatan.

I build AI systems that help pharma and biotech teams move drugs from hypothesis to patient — faster and with better evidence.

Currently co-founder at Apxora, head of data science at AlphaMeld GmbH (formerly InveniAI GmbH), and CTO at Artixio — where I'm building QuriousRI. Based in Basel.

18y experience · 5+ platforms · 12+ ML models · 4 patents
Sanatan Upmanyu

Selected work

all work

  • AlphaMeld® Operating System

    Compresses hypothesis-to-insight cycles from months to weeks, varying by disease area

    End-to-end AI stack combining a custom UI layer (Knowledge Graph, ChatAlphaMeld, Bioinformatics, Literature Analysis, AlphaClinMeld) with 12 ML models — including NER, RE, evidence scoring, digital-twin CT predictors and landscape assessment — running on PostgreSQL + Neo4j and self-hosted GPT/Claude custom APIs.

  • Discovery Navigator

    Hypothesis landscaping compressed from weeks to hours, with traceable evidence at every step

    Guided drug-discovery hypothesis-generation platform built on the AlphaMeld Knowledge Graph. Supports four starting points — disease-first, target-first, indication expansion, and combination therapy — through a step-by-step workflow (project → config → exploration → agent scoring → ranking → hypotheses). A project-aware Discovery Copilot accompanies every step. Multi-tenant SaaS with SSO, RBAC, and audit logging.

  • QuriousRI

    Drug & biologic regulatory intelligence spanning 12+ agencies — FDA, EMA, PMDA, NMPA, Health Canada, MHRA, Swissmedic, and more

    Secure, role-based platform for pharma/biotech regulatory affairs teams to search, analyze, compare, and manage global drug and biologic approvals. Covers pharmaceuticals, biologics, biosimilars, and generics across 12+ regulators. Combines role-based dashboards, pathway and classification guides, dossier preparation support, a centralized guidelines library, Q&A with expert responses, and AI-assisted document analysis (GPT-4, Claude).

  • Pipeline Alpha

    Tracks ~10,000 clinical-trial drugs and AI-predicts the catalysts that move small-cap biotech stocks

    Investment research platform for small/mid-cap NASDAQ biotechs where a single trial readout can move the stock 50%+. Syncs clinical-trial data (ClinicalTrials.gov, Clinical Navigator) with live stock and financials (Alpha Vantage), then runs LLM catalyst discovery and streaming AI predictions for upcoming readouts, PDUFA dates, partnerships, and conference events. Includes bulk catalyst briefings and an interactive research chat.

Work together

Advisory engagements, speaking invitations, and technical consulting for pharma, biotech, and consumer health.

Get in touch